UK Regulator Reports 150,000 Adverse Events and 153 Deaths Linked to Weight-Loss Jabs
UK data links 150+ deaths to weight-loss jabs. A new study finds a vegan diet led to 5.9kg average loss in 4 months vs 6.9kg over 9 months for semaglutide.
Saxenda
DrugDrug Profile
Saxenda is the brand name for liraglutide, a GLP-1 receptor agonist used with reduced-calorie diet and increased physical activity for chronic weight management in eligible adults and adolescents aged 12 years and older. The label describes appetite and calorie-intake regulation through GLP-1 receptor activity in the brain. U.S. labeling lists initial approval in 2010.
- Drug Class
- Glucagon-like peptide-1 (GLP-1) receptor agonist
- Approval Status
- FDA approved (Initial U.S. Approval: 2010)
- Mechanism of Action
- Acylated human GLP-1 receptor agonist that activates GLP-1 receptors involved in appetite regulation and reduces calorie intake.
- SAXENDA
- \Chronic weight management in adults and pediatric patients aged 12 years and older with body weight >60 kg and obesity\
- \Chronic weight management in adults with overweight and at least one weight-related comorbid condition\
Related News
Semaglutide Linked to Lower Seizure and Alcohol-Related Hospitalization Risks; Brazil Approves Five New GLP-1 Drugs
Semaglutide may lower risks of adult-onset seizures and alcohol-related hospitalizations, new studies find. Brazil approved five semaglutide injectables, and a commentary updates obesity care with GLP-1 drugs.
GLP-1 Drugs: Smell and Taste Risks, Soaring Poison Calls, and Reshaped Food Demand
GLP-1 receptor agonists are linked to a higher risk of smell and taste disturbances, while poison control calls involving semaglutide have soared since 2021. The drugs produce significant weight loss and are reshaping U.S. food demand, with roughly one in eight adults now taking them.
GLP-1 Drugs Show Mixed Effects on Brain Health: Neuroprotection Signals but Dementia Risk Questions
A Johns Hopkins study found GLP-1 users face increased dementia risk after a decade, possibly due to longer lifespan. A separate JCI review found GLP-1 drugs show neuroprotective signals in preclinical studies but consistent cognitive benefits in humans remain unproven.
Novo Nordisk Cuts GLP-1 Drug Prices Up to 50%; WADA Monitors Use, Brazil Reports 65 Deaths
Novo Nordisk will reduce prices for Wegovy, Ozempic, and Rybelsus by up to 50% starting January 2027. Meanwhile, WADA investigates potential Olympic ban on weight loss drugs, and Brazil's Anvisa reports 65 suspected deaths linked to GLP-1 medications.
Semaglutide and Other GLP-1 Peptides Show Significant Weight Loss Results in Clinical Studies
Semaglutide and other GLP-1 receptor agonists demonstrate substantial weight loss effectiveness through appetite regulation and blood sugar control, with clinical studies showing average reductions of 14.9% to 20.9% body weight.
Related Clinical Trials
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT06217848 |
The Effect of GLP-1 Agonist in Patients With Hypothalamic Obesity: Prospective, Pilot Study |
RECRUITING | EARLY_PHASE1 |
| NCT05111912 |
Effects of XW003 Versus Liraglutide on Body Weight of Adult Participants With Obesity |
COMPLETED | PHASE2 |
| NCT03885297 |
3mg Liraglutide for Overweight or Obesity |
COMPLETED | |
| NCT03115424 |
Effect of GLP-1 Receptor Agonism After Sleeve Gastrectomy |
COMPLETED | PHASE3 |
| NCT03048578 |
Clinical Efficacy and Safety of Using 3.0mg Liraglutide to Treat Weight Regain After Roux-en-Y Gastric Bypass Surgery |
COMPLETED | PHASE4 |
| NCT03036800 |
Saxenda in Obesity Services (STRIVE Study) |
COMPLETED | PHASE4 |